41 related articles for article (PubMed ID: 38660140)
21. Chaperone-mediated autophagy degrades mutant p53.
Vakifahmetoglu-Norberg H; Kim M; Xia HG; Iwanicki MP; Ofengeim D; Coloff JL; Pan L; Ince TA; Kroemer G; Brugge JS; Yuan J
Genes Dev; 2013 Aug; 27(15):1718-30. PubMed ID: 23913924
[TBL] [Abstract][Full Text] [Related]
22. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?
Choudhury S; Kolukula VK; Preet A; Albanese C; Avantaggiati ML
Cell Cycle; 2013 Apr; 12(7):1022-9. PubMed ID: 23466706
[TBL] [Abstract][Full Text] [Related]
23. Multiple stress signals activate mutant p53 in vivo.
Suh YA; Post SM; Elizondo-Fraire AC; Maccio DR; Jackson JG; El-Naggar AK; Van Pelt C; Terzian T; Lozano G
Cancer Res; 2011 Dec; 71(23):7168-75. PubMed ID: 21983037
[TBL] [Abstract][Full Text] [Related]
24. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
25. The first 30 years of p53: growing ever more complex.
Levine AJ; Oren M
Nat Rev Cancer; 2009 Oct; 9(10):749-58. PubMed ID: 19776744
[TBL] [Abstract][Full Text] [Related]
26. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Terzian T; Suh YA; Iwakuma T; Post SM; Neumann M; Lang GA; Van Pelt CS; Lozano G
Genes Dev; 2008 May; 22(10):1337-44. PubMed ID: 18483220
[TBL] [Abstract][Full Text] [Related]
27. Live or let die: the cell's response to p53.
Vousden KH; Lu X
Nat Rev Cancer; 2002 Aug; 2(8):594-604. PubMed ID: 12154352
[No Abstract] [Full Text] [Related]
28. Early stages of p53-induced apoptosis are reversible.
Geske FJ; Lieberman R; Strange R; Gerschenson LE
Cell Death Differ; 2001 Feb; 8(2):182-91. PubMed ID: 11313720
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation.
An WG; Chuman Y; Fojo T; Blagosklonny MV
Exp Cell Res; 1998 Oct; 244(1):54-60. PubMed ID: 9770348
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
31. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers.
Martinho MS; Nancarrow DJ; Lawrence TS; Beer DG; Ray D
Cell Mol Gastroenterol Hepatol; 2021; 11(2):449-464. PubMed ID: 33130332
[TBL] [Abstract][Full Text] [Related]
32. GOF Mutant p53 in Cancers: A Therapeutic Challenge.
Dolma L; Muller PAJ
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291874
[No Abstract] [Full Text] [Related]
33. Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.
Oduah EI; Sharfstein ST; Seetharamu N; Grossman SR; Litovchick L
Front Oncol; 2024; 14():1363543. PubMed ID: 38660140
[TBL] [Abstract][Full Text] [Related]
34. Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Oduah EI; Grossman SR
Cancer Biol Ther; 2020 Apr; 21(4):293-302. PubMed ID: 32041464
[TBL] [Abstract][Full Text] [Related]
35. Targeting mutant p53 stabilization for cancer therapy.
Wang J; Liu W; Zhang L; Zhang J
Front Pharmacol; 2023; 14():1215995. PubMed ID: 37502209
[TBL] [Abstract][Full Text] [Related]
36. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
